- vor 12 Minuten
Europas Gesundheitssystem: Grundrecht oder Geschäftsmodell? EU-Abgeordnete debattieren in The Ring
Spezialausgabe von The Ring vom Euronews Health Summit: Die EU-Abgeordneten Stine Bosse und Tilly Metz debattieren, wer Europas Gesundheitsinnovationen finanziert.
LESEN SIE MEHR : http://de.euronews.com/2026/03/19/europas-gesundheitssystem-grundrecht-oder-geschaftsmodell-eu-abgeordnete-debattieren-in-th
Abonnieren Sie! Euronews gibt es in 12 Sprachen.
Spezialausgabe von The Ring vom Euronews Health Summit: Die EU-Abgeordneten Stine Bosse und Tilly Metz debattieren, wer Europas Gesundheitsinnovationen finanziert.
LESEN SIE MEHR : http://de.euronews.com/2026/03/19/europas-gesundheitssystem-grundrecht-oder-geschaftsmodell-eu-abgeordnete-debattieren-in-th
Abonnieren Sie! Euronews gibt es in 12 Sprachen.
Kategorie
🗞
NewsTranskript
00:08Welcome to The Ring, to this very special edition, broadcasting live here from downtown Brussels.
00:15My name is Maeve McMahon and I'm one of the presenters of The Ring,
00:18which is our weekly debating show that sees MEPs go face-to-face on some of the most pressing issues
00:25of our time.
00:26The topic that we're jumping into today is healthcare and who should pay.
00:32Europe is facing spiraling healthcare costs driven by an aging population and chronic diseases.
00:38At the same time, demand for new treatments is growing, raising crucial questions.
00:44Who should pay for healthcare innovation and to what extent is health treated as a business?
00:50One key pressure point is the cost of new drugs and vaccines.
00:54Should the EU coordinate pricing for essential medicines to ensure equal access across member states,
01:00while also having tools to intervene in production and distribution during crises?
01:05Or should pricing and supply remain a national responsibility to prevent straining healthcare budgets and weakening market incentives?
01:14Tax debates in the pharmaceutical sector further highlight concerns about how much the industry should profit from public investment.
01:21Europe also faces longer-term challenges.
01:25Its healthcare system spends far more on treatment than prevention.
01:29The real question is not only how Europe will pay for healthcare,
01:33but what kind of healthcare system it ultimately wants to protect.
01:38Let's meet our panelists.
01:42Tillie Metz, a Luxembourgish MEP from the Greens European Free Alliance Group.
01:47She has been a member of the European Parliament since 2018 and serves in the Committee on the Environment, Public
01:53Health and Food Safety.
01:55In debates on EU health policy, she has advocated for stronger European cooperation on public health and greater transparency in
02:03the pharmaceutical sector.
02:04We need a strong commitment to solidarity over privatization and to high-quality care over commercialization, she said.
02:13Stine Boss, a Danish MEP from the Liberal Renew Europe Group.
02:17Elected to the European Parliament in 2024, she works on economic and industry-related issues
02:23and has spoken about the importance of maintaining Europe's competitiveness and innovation capacity.
02:28In discussions about the pharmaceutical sector, she has emphasized the need to balance strong research incentives with sustainable healthcare systems.
02:36We must do much more, better and cheaper together, including by creating a single market for clinical trials
02:43and by taking more decisions at the European level, she said.
02:50Welcome. So lovely to have you with us here for this very special edition of The Ring.
02:55So the idea here, ladies, is to give our viewers back home a bit of a taste of what exactly
03:01you get up to inside that European Parliament chamber,
03:04here in Brussels and also in Strasbourg.
03:07Sometimes you fire questions at each other, sometimes it gets a little bit heated.
03:11Today, as you know, we're focusing on healthcare and the future of it right here in the European Union,
03:17and who, of course, should pay.
03:18So Tilly, if we can start with you on that very, very pertinent question,
03:22who should be paying for the future of healthcare in Europe?
03:25Should it be us, the patients? Should it be pharma, the governments, big tech?
03:29Yeah, but if we look what the situation is right now,
03:33we see there's a lot of public funding indeed going in research,
03:37but there's also the patient that is paying.
03:40So you could even say that the patient right now is paying twice.
03:43He is paying first with taxes, which go down to funds,
03:48and then he pays again a price at the pharmacy.
03:52So what we need for sure is at the EU level, but also at national level, more public investment.
03:59Well, it actually all connects, and I do agree that there is an issue on how do we look into
04:07the future?
04:08What is the construction?
04:09Is it all, you know, everybody has access to healthcare, or is it a different model?
04:15That has to be debated.
04:16But at the end of the day, it all starts and it all ends at the end of the day
04:21that we have a strong and competitive pharmaceutical sector,
04:24and then we can discuss who pays.
04:27And that's an important point, of course.
04:29Tillimeth, if you look at the data, one in every two medicines,
04:33this is back 25 years ago, was invented or discovered right here in Europe.
04:38Now it's only one in six.
04:39What went wrong?
04:41Exactly.
04:42I mean, if we go more to privatization and more leaving all the leadership to the pharma industry,
04:48we see that it doesn't work.
04:50Indeed, we still have innovation in Europe.
04:52We still have, but we are not really scaling up.
04:55But if we look at innovation and there is no real added value for the patients,
05:00that's something we need to do better.
05:02So it's up to public authorities to take back their leadership and their responsibility.
05:09I mean, if we go more and more in private health care,
05:13there is a huge risk of even more commercialization of access to health care
05:19and of commodifying medicines and health care.
05:22Would you agree with that point, Sinebos?
05:24Yes, I do agree, but I don't think that a strong pharmaceutical sector
05:29is the opposite of having a totally sane and fantastic health care sector as such.
05:36I think these two things go hand in hand.
05:39But that is, of course, a question of funding.
05:41First of all, importantly enough, funding for the pharmaceutical sector.
05:45And then, of course, who pays?
05:47Is it tax paid?
05:48Is it universal access to treatment and to medicines?
05:52Or is it a private sector that we see growing?
05:55And there, I think, we will have to face that there will be a blend.
05:59And I am a strong believer in a strong universal health care sector
06:06that makes sure that there is access for everybody.
06:09I mean, we know that the private sector and the objective of the private sector
06:14are not necessarily aligned with what is really the public health's need.
06:20But I agree, we need a strong pharma sector.
06:24We need to have manufacturing back in Europe.
06:27And we need to have the conditions.
06:29But the incentives for the pharma industry must not rely only on intellectual property rights.
06:37There are other models, other alternatives of incentives.
06:41There needs to be a better coordination from the public authority in order to make it more equal.
06:48And this issue of scaling up, how can we do better here?
06:51I mean, in Europe, we're great at research, we're great in the lab,
06:54but getting it to market then is always the big challenge.
06:56Yeah, and there I tend to disagree.
06:59So without letting go of the security level for our citizens,
07:04we should base much more on our EMA and less on our national entities.
07:11Because if you look at it, it is 578 days from the approval of a medicine in EMA,
07:21till it reaches the patient.
07:22And on the European Medicine Agency, we'll come back to that point.
07:25I didn't say that it should not be the European Medicine Agency.
07:28I'm very pro-European.
07:29On contrary, we need better cooperation between the member states,
07:33and that can only be done at European level.
07:36I mean, on that I agree with you.
07:38And is the European Union ready for the next big pandemic?
07:41Because we know it's coming.
07:42I mean, we remember those terrible days of COVID,
07:44and we're being warned that the next pandemic is around the corner.
07:47Sinebos, is the EU ready for this?
07:49No.
07:50I mean, we are more prepared than we were.
07:52I mean, we have learned.
07:54And the institutions are also now stronger,
07:57and health is a stronger issue.
08:00You know, the fact that we now have the health committee,
08:02and it's a full committee, and so on.
08:04All these things point in the right direction.
08:05But that's not reassuring our viewers, just having a committee.
08:07No, I agree.
08:09And here, I'm back to that.
08:11We need also a stronger collaboration between countries within the union.
08:17We need links also for ongoing health care,
08:20not only on the innovation side, but also on the delivery side,
08:24also between the hospitals.
08:26There's so many things that we can do a lot better and cheaper together
08:30if we work pan-European on these subjects.
08:34But I think one thing that we definitely learned from the pandemic
08:37is that we are over-reliant to the pharma industry.
08:41So we need the public sector to take more responsibilities again
08:45and to have a better coordination.
08:46To be too reliant to the pharma industry, I mean, that gives a lot of insecurities
08:52also regarding the supply chain, regarding the transparency on the real coast,
08:57on research and development.
08:59I mean, I'm not against a strong pharma industry,
09:02but we must definitely also consider to have a European infrastructure
09:07on research and on production also of medicine.
09:12And I think we need to be ambitious there in order not to be too reliant and dependent
09:17only on the private sector, where we all agree that they have different objectives
09:24and that is also perfectly okay.
09:26I mean, as I say, they are not necessarily aligned with what is really an added value
09:31of the medication.
09:32That's why there are certain sectors like the orphan medicines,
09:37but also the antibiotics, where the pharma industry is not really interested
09:41because it's not really financially interested.
09:44So the objectives are different and that's why we need a stronger public leadership
09:49of public authorities.
09:50That's the view from Terry Metz.
09:51Let's hear your view there.
09:52You might have recalled that I'm not a socialist,
09:55but I do have a lot of social responsibility within the way I think about our citizens.
10:03So I cannot see, Tilly, that we should go for a fantastic publicly owned pharmaceutical sector.
10:11I think we need a strong privately owned, privately financed pharmaceutical sector
10:17who can see the benefits of staying in Europe, developing in Europe
10:21and delivering in Europe.
10:22And we also, of course, want to hear from you.
10:24You can always write to us at TheRing at Eurinews.com.
10:27We'll come back to it.
10:28Okay.
10:32Now it is time for our viewers to get a real taste of Inside the Chamber,
10:36when MEPs actually fire questions at each other.
10:39So now I'd like you to start with your first question for Tilly Metz.
10:42Well, Tilly, I just want to know, how on earth are you going to make sure that we can be
10:49able from Europe
10:50to deliver the best, the newest medicines, the fastest to our citizens?
10:57What is your prescription for that?
11:01I think it's very clear that we need to give incentives to the pharma industry
11:06and, on the other hand, to have kind of safe net by a public infrastructure.
11:12In order to have innovation and to guarantee also accessibility to innovation to everybody,
11:19we need to put conditions on this public funding
11:23and we need public authorities to play their role on asking accountability to the pharma industry
11:31and on asking transparency on the R&D costs, but also on how they develop their prices.
11:38I mean, as I said at the very beginning, it cannot be that the patient pays two times or three
11:44times,
11:45once by the data, once by the taxes that he pays, and then again a high price at the pharmacy.
11:52Are you satisfied with that answer or would you like to follow up?
11:55No, because I still see that there is a high risk with all your good ideas,
12:00some of them we can agree on, but there is a high risk that the pharmaceutical sector
12:04would look to other grounds and say, you know, it's much more attractive to us
12:09to develop and to invest in the U.S., for example, so bye-bye.
12:13Do you agree with the U.S. system where indeed the pharma industry wants to put very much higher prices?
12:22I mean, that's what they want.
12:23That's why they are attracted by the market in the U.S.
12:25Is that the model that we should aim at?
12:28No.
12:28Where only an elite can offer treatment and have innovation access and innovative healthcare?
12:35No, I think we must definitely take our responsibility,
12:39and that is one of the lessons learned from the pandemic.
12:42And that is, Tina, that's what we are working on, the Critical Medicines Act.
12:46It's exactly what we are doing there.
12:48We are making that the EU takes more responsibility in coordination,
12:54what is critical medicine for the citizens and what is really also of an added value
12:59and how we can bring back manufacturing again back to Europe.
13:03That's what we are working on, on the Critical Medicines Act.
13:06And our viewers can read more about that Critical Medicines Act on yournews.com.
13:09But now, Tilly Metz, it is time for you to address your very first question, Justine Boss.
13:13Yeah, but my very first question, I said it already a little bit,
13:16is like, do you agree, in order to have accessibility and affordability on medicine,
13:23that we need to have more transparency on coast?
13:27And that is meaning, when we give public funding to the pharma industry,
13:31that we need to put conditions on this public funding.
13:36Conditions like supply chain, transparency on coast, etc.
13:42I think, first of all, and I will be repeating myself slightly, so bear with me.
13:46I think that it's the starting point will be that we have a strong pharmaceutical sector.
13:51And you might not agree, you think you jump right into it has to be state-owned
13:55and it has to be state-funded.
13:57I'm on another page there.
13:59Then, having said that, then I agree that there are areas,
14:03the Critical Medicines Act is a good example,
14:05but there are also other areas where we have to think differently,
14:09as Europeans, but also as countries.
14:12And that's why this thing about the nearly 600 days to approval,
14:17that we have to get out.
14:19We need to make sure that the country's level of approval is not there.
14:25It doesn't make any difference.
14:27And then on top of that, if we say to ourselves that there's an 80% difference
14:31between the countries of the accessibility to medicines,
14:35Of course, that cannot be so.
14:37So we have a huge issue at our hands to level this out between countries
14:42and to protect our universal healthcare.
14:45But that is only protected if we have earnings.
14:49Earnings makes taxes.
14:51Taxes makes the money to actually finance healthcare.
14:55I know you had another long list of questions for each other,
14:57but we will have to wrap it there because we've now heard from our MEPs
15:02and I would really like to bring in another voice here.
15:08I would like to bring in the voice now of the head of AstraZeneca,
15:12the CEO and executive director, that's Pascal Sochiot.
15:15He recently said that the pharma industry in Europe
15:18will be reduced to a shadow of itself within 15 years.
15:22He said this due to two major threats facing the pharma industry.
15:26One, pharma companies are investing heavily in the US to avoid heavy taxes
15:30by the Trump administration and, of course, the other elephant in the room.
15:34China is, of course, the leader in generics and a major competitor
15:38when it comes to innovation medicines.
15:40So, Tilly, Matt, I'm curious to hear your view here
15:43on the concerns of the industry and of the CEO there of AstraZeneca.
15:47First of all, what I want to correct,
15:49because it seems like I want 100% only state-owned pharma industry.
15:55That is wrong.
15:56I just want a safe net that is public
16:00in order to guarantee that we are not 100% lying.
16:04But the pharma industry has an important role to play.
16:09And I spoke about incentives.
16:10I'm just convinced, and we see it in the reality,
16:14if we are pragmatic, we see in the reality,
16:17leaving it all to the pharma industry,
16:19that the system doesn't work,
16:20because we have shortage of medicine, etc.,
16:23what I said before.
16:25But we need other incentives, like the subscription model,
16:29where you know if you work on research,
16:31for example, on antibiotics,
16:33that you get the fixed amount of money
16:35in order to work on that.
16:37That is one model.
16:37Or a milestone model.
16:39So, Ancine, if I can just bring you in here,
16:43I mean, is it scaremongering what he says there?
16:45Or would you agree with it?
16:46Because, I mean, you're still the home of a big pharma.
16:49And I think it's actually more serious
16:50than we can dream of.
16:52We are, and this is a little bit dramatic,
16:54but it's good on television,
16:56we are under attack.
16:58I mean, our pharmaceutical sector
17:00is under attack.
17:01This idea of the nation,
17:06most favored nation legislation
17:08that the administration in the U.S. put in place
17:12is really, really hammering us.
17:15And I'm not saying that we should give up,
17:18and I agree with you on the fact
17:20that there should be a basis coverage,
17:22obviously, for citizens in Europe,
17:24also regarding the safety of the approvals.
17:27But we have to understand
17:29that we must fight this
17:31with giving terms and conditions
17:34to our pharmaceutical sector
17:36that can compete with this,
17:38in my opinion,
17:39very mean model,
17:40and that we have to fight back.
17:42Would you agree with this,
17:43what she calls a very dramatic statement?
17:44Let's look what is at the center
17:46of our concerns.
17:47And I am allowing myself to say
17:50that it is different as a politician
17:51than from the pharma industry perspective.
17:54At the center of our concern
17:56is the patient.
17:57If you look at the situation
17:58of the patients in the United States,
18:00they are in a much worse health situation.
18:04If you look mental health,
18:05if you look obesity,
18:06if you look at a lot of diseases,
18:09suicide, everything,
18:10they are in a much worse case.
18:12What do I have from innovation
18:14if it's not accessible for the large public?
18:17And in innovation,
18:18we are not bad in Europe.
18:20It's in scaling up,
18:21it's in manufacturing
18:22where we are leaking.
18:23And we have a very fragmented market
18:25as well, Sinebos.
18:26Sure, we have this fragmented market
18:28and we have really not a capital union, right?
18:31So we need also the fact
18:33that investors should have a much,
18:36or yeah, investors and companies,
18:37much easier access to capital
18:39to make them stay here.
18:41We also have to face, Tilly,
18:44that no matter how we turn this around,
18:46there needs to be a strong sector here.
18:49We need to understand
18:50what the problems is for the sector,
18:52try and solve them
18:53and then of course fight back to the US
18:55because I agree,
18:57even long liberty is much better in Europe
18:58and we should not give up on these areas
19:01but it's not on the contrary
19:03to have a strong sector.
19:05And then it comes back to the first question,
19:07who is paying?
19:08And there I think there is a need for a truly
19:12and deep discussion on transparency,
19:15on how do we actually have fun
19:17because our model,
19:18look, our model is like 80% gets everything, right?
19:23We covered a lot of people.
19:25That's why we buy a lot of pharmaceutical products
19:28at a cheap price.
19:30In the US,
19:31not a lot of people are covered
19:33so they pay much more per pill.
19:36So that makes it completely uncomparable
19:38and that we have to sit down
19:40and really investigate and find out
19:43also in the Biotech Act,
19:44how are we going to solve this?
19:46So you have a lot to do, ladies,
19:48but now it is time in fact
19:49for our next round.
20:00Now I'd like to bring in some figures.
20:02There is a big problem
20:03when it comes to Europeans
20:04having to wait for new medicines.
20:06The EU average is about 578 days.
20:10That's from approval to patient access.
20:13And it varies from country to country.
20:15Patients in some countries
20:17have to wait seven times longer than others.
20:20While the fastest is in Germany
20:22at 128 days,
20:24Portuguese patients wait the longest.
20:26So your reaction here to this inequality?
20:28Yeah, this is completely how it is.
20:32But of course there is an explanation.
20:35It's not because Portugal wants
20:37to have a longer period for the population.
20:41It's about finances.
20:42It's about can they afford it?
20:44And here we are, of course,
20:45entering into very, very difficult discussions
20:48because a country like Denmark
20:50if you compare us to Bulgaria, to Romania,
20:53then we are in for big,
20:55you know, there's a big difference.
20:57And that we need to over time solve.
21:00But one of the ways to do it
21:02is to, again,
21:03what we can make better and cheaper together,
21:05we must, including the EMA,
21:07to save all the money
21:08in all the countries.
21:10And the irony is in Germany,
21:11128 days, that's supposed to be quick.
21:14I mean, that's a matter of life and death
21:15if you have to wait that long for your pills.
21:16Yes.
21:17Yeah, indeed.
21:18And what we need also
21:20is we need more cooperation
21:22in European procurement
21:24so that we do,
21:26that we buy together
21:27in order also with strict timeline
21:30and also with the security
21:31on the supply chain.
21:33So that's, again,
21:34we need to give more incentives.
21:36That is true.
21:37But that goes hands in hand
21:39with conditions of supply chain, etc.
21:42And we need, of course,
21:44on that I agree with Sinebos,
21:45we need also to keep the EMA,
21:47the European Medicines Agency,
21:49more human resources
21:50and more resources in general
21:52in order to be more efficient.
21:54And then that we need less and less
21:56also there to rely on national issues.
21:59And should there be an EU-wide pricing
22:01for essential medicines?
22:03I think at the end of the day,
22:04we will get into that area.
22:07I don't see that we can avoid
22:09having some kind of, you know,
22:11more transparency
22:12and more central discuss pricing.
22:15Because now when you go to your doctor,
22:16sometimes they say,
22:17go to France, you can get...
22:17Yeah, yeah, yeah, yeah.
22:18Yeah, yeah.
22:19That's why I say,
22:20but I had this conversation with,
22:21you can probably guess who it is,
22:23but it was a CEO
22:24of a large Danish pharmaceutical company.
22:27And I said to him,
22:29I don't worry when I go in a shop
22:31and I buy,
22:32like say H&M,
22:33and I buy something.
22:34And I can see the price in Sweden,
22:36in Germany,
22:37in France.
22:38I'm still happy paying with my,
22:40unfortunately,
22:41it's still Danish kroner.
22:43So I think we should be more transparent,
22:47we should be more bold
22:49together with the industry.
22:50And they are also,
22:51at least some of them,
22:53maturing in that direction.
22:55Of course,
22:56also because of the big threat
22:57that we have just debated
22:58from the outside.
23:00Now,
23:00we definitely need to put
23:01public interest,
23:02it's definitely more important,
23:04especially in the health sector,
23:05than commercial interest.
23:07I mean,
23:07at the very end,
23:09the very famous company,
23:11pharma industry,
23:11that produced drugs in,
23:12in the last moment,
23:14the price was really increasing again.
23:16Why?
23:16All the research,
23:17all the A&D was done,
23:19so we need definitely transparency.
23:21And as I said,
23:21that goes hand in hand
23:23with also public funding.
23:25It's something we owe
23:26to the taxpayers,
23:27we owe to the citizens
23:29to ask for this transparency.
23:31And especially when we speak
23:33of a fundamental right,
23:34which is access to healthcare.
23:36Because as you said,
23:38twice or three times
23:38or four times already
23:39here in the program,
23:40consumers are paying twice,
23:42patients are paying twice.
23:43This is a big problem.
23:44Well,
23:45I'm not sure I agree completely
23:46on the fact that people
23:48are paying twice.
23:50I agree
23:50that there is a debate
23:52on how can we make
23:53this more transparent.
23:54But to be honest,
23:55I mean,
23:56the pharmaceutical sector
23:58invests a lot
23:59and they should.
24:00And I also agree
24:02that in some areas
24:03they should also
24:03be held accountable.
24:05You know,
24:05if there is public money involved.
24:07Yes,
24:08I agree on that.
24:09Shall we speak about
24:10the benefits that we made
24:11for the COVID-19?
24:12Yes,
24:13but look,
24:14then on the other hand,
24:15of course,
24:15there is
24:16large number
24:17of workplaces,
24:19innovation,
24:21you know,
24:21attracting skilled people
24:23and all this
24:24is also beneficial
24:25for Europe.
24:26It's not only,
24:27it's not a non-sum spill,
24:29you know,
24:30thing.
24:30We have to look
24:31at the total.
24:32And I think
24:33it is,
24:34it would be devastating
24:35if we lost
24:36the last industry,
24:38ladies and gentlemen,
24:39the last industry
24:40where we are still
24:41close to,
24:42not even,
24:43but close to
24:44on par
24:45with the US
24:46and China.
24:47We lost
24:48the digital industry.
24:49So do we want
24:50in 10 years from now
24:52to have a pharmaceutical sector
24:53where we said
24:53that's history,
24:54it's gone.
24:55And on the digital industry,
24:56that's of course
24:56for another episode
24:57of The Ring.
24:58We'll have to wrap it up there
24:58because I would love
24:59to move on
25:00to the fifth
25:01and very last round
25:02of this very special edition
25:03of The Ring
25:04which is focusing
25:05on the future
25:05of healthcare.
25:10Ladies,
25:10are you ready?
25:11Yeah.
25:12Excellent.
25:12Because you need
25:13all your wits about you
25:14for this last segment
25:16because it's a little
25:16bit different.
25:17You only are allowed
25:18to answer using
25:19yes or no.
25:21Does that sound good?
25:22That sounds good.
25:23Great.
25:24Let's do it.
25:24Stine Boss,
25:25let's begin with you.
25:26Should the EU
25:27cap prices
25:27for essential medicines?
25:29Yes or no?
25:35Can I have a yes,
25:36but?
25:37Very briefly.
25:38Yes,
25:39but it has to be
25:40limited to very,
25:41very special situations
25:43and very special medicines.
25:44Okay,
25:44let's see if you can do
25:45a yes or no here.
25:46Yes,
25:47it's a fundamental right.
25:48Access to fundamental medicines
25:49is a fundamental right.
25:51Another question
25:52coming for you both.
25:53Tilly,
25:53I will start with you.
25:54Should Brussels
25:55negotiate drug prices
25:56for all EU member states?
25:58I think that would be
25:59a strength
25:59if we do that.
26:00We saw the COVID-19
26:01that negotiating together
26:04gives us more power.
26:05So yes.
26:06So that's a yes.
26:06What about you?
26:07Yes or no on this one?
26:08Down the road,
26:09it will be a yes
26:10from me also.
26:12Should patients
26:12be waived
26:13during major health crises?
26:15Yeah,
26:15yeah,
26:15of course.
26:16I mean,
26:16the patients
26:17and this is this.
26:18You say yes,
26:18I say yes
26:19to the fact
26:20that you need,
26:21we need,
26:22we're politicians,
26:23we need to keep
26:24our main focus
26:25on the patients.
26:26No doubt about that.
26:27And now a question
26:28you're both going to love.
26:29Should medicines
26:29be the same price
26:30all across the European Union?
26:33That's a long way
26:33to go there,
26:35but that would be coherent
26:37if we listen
26:38to the European citizens
26:39that want more healthcare
26:41and also better coordinate.
26:42So that's a big yes,
26:43a resounding yes.
26:44What about you?
26:44I mean,
26:45it goes hand in hand
26:46with what I just answered.
26:47So if you have a procurement
26:50way down the road
26:51that is common European,
26:53then of course
26:54you also have
26:54a transparent common policy.
26:56And just finally,
26:56is the future
26:57of EU health
26:58and innovation bright?
27:01Yes,
27:02I'm a strong believer
27:04in the EU as such
27:05and of course
27:05also in this sector,
27:06but we have to get
27:07a lot of our act together.
27:08And what about you?
27:09Yes or no?
27:09Bright future or not?
27:11Bright future,
27:12yes,
27:12because we should listen
27:13to the citizens
27:14and we should put more funding
27:15and not cut the funding.
27:16Telly Meiss,
27:17did you agree
27:17with anything you've heard?
27:18Yes,
27:19she said that we should waive
27:20the intellectual property
27:21rights during a pandemic.
27:22There you go.
27:23You see,
27:23it's here on the ring
27:24where we get people to talk,
27:25disagree and sometimes agree.
27:27Thank you so much
27:28and a round of applause
27:28for our two
27:30MEPs on the ring,
27:30Sine Boss and Tilly Meiss.
27:32Thank you.
27:37And thank you so much
27:38for tuning in.
27:39As always,
27:39we love to hear from you.
27:40Write to us at
27:41The Ring
27:41at Euronews.com
27:43and stay with us here
27:44on Euronews.
27:50Euronews.
Kommentare